Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine

被引：0
作者：
Mani Kandasamy
P. Srinivas
Kala Subramaniam
Sandhya Ravi
James John
Radha Shekar
Nuggehally Srinivas
Saral Thangam
机构：
[1] Lotus Labs,Biometrics
[2] Lotus Labs Pvt. Ltd.,Bioanalytical
[3] Lotus Labs Pvt. Ltd.,Clinical
[4] Suramas Biopharm,Drug Development
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
CYP2D6; Venlafaxine; O-desmethyvenlafaxine; Pharmacokinetics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：879 / 887
页数：8
相关论文
共 50 条
  • [31] Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resin
    Al-Jenoobi, Fahad I.
    Al-Thukair, Areej A.
    Alam, Mohd Aftab
    Abbas, Fawkeya A.
    Al-Mohizea, Abdullah M.
    Alkharfy, Khalid M.
    Al-Suwayeh, Saleh A.
    SAUDI PHARMACEUTICAL JOURNAL, 2014, 22 (06) : 564 - 569
  • [32] The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis
    Quyen Thi Tran
    Baek, In-Hwan
    Han, Na-Young
    Yun, Hwi-Yeol
    Chae, Jung-Woo
    PHARMACEUTICS, 2022, 14 (07)
  • [33] Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes
    Yang, Yujie
    Zhang, Xiqian
    Wang, Yirong
    Xi, Heng
    Xu, Min
    Zheng, Liang
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [34] The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report
    Kuzin, Maxim
    Scharrer, Isabel
    Nolan, Daniele
    Baumgartner, Markus
    Paulzen, Michael
    Schoretsanitis, Georgios
    Xepapadakos, Franziskos
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 127 (04) : 354 - 357
  • [35] Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood
    Kingback, Maria
    Karlsson, Louise
    Zackrisson, Anna-Lena
    Carlsson, Bjorn
    Josefsson, Martin
    Bengtsson, Finn
    Ahlner, Johan
    Kugelberg, Fredrik C.
    FORENSIC SCIENCE INTERNATIONAL, 2012, 214 (1-3) : 124 - 134
  • [36] Influence of the CYP2D6 Isoenzyme in Patients Treated with Venlafaxine for Major Depressive Disorder: Clinical and Economic Consequences
    Sicras-Mainar, Antoni
    Guijarro, Pablo
    Armada, Beatriz
    Blanca-Tamayo, Milagrosa
    Navarro-Artieda, Ruth
    PLOS ONE, 2014, 9 (11):
  • [37] Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene
    Novillo, A.
    Romero-Lorca, A.
    Gaibar, M.
    Rubio, M.
    Fernandez-Santander, A.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (02) : 109 - 111
  • [38] The metabolic profiles of endogenous and exogenous substances in a poor metabolizer of humanized CYP2D6 model
    Qian, Jianchang
    Wang, Yahui
    Kong, Qihui
    Chai, Huiyan
    Hu, Haidan
    Chen, Lianguo
    Hu, Lufeng
    Zhang, Qianwen
    Hu, Guoxin
    Chen, Bingbing
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 203
  • [39] Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data
    van der Lee, Maaike
    Allard, William G.
    Vossen, Rolf H. A. M.
    Baak-Pablo, Renee F.
    Menafra, Roberta
    Deiman, Birgit A. L. M.
    Deenen, Maarten J.
    Neven, Patrick
    Johansson, Inger
    Gastaldello, Stefano
    Ingelman-Sundberg, Magnus
    Guchelaar, Henk-Jan
    Swen, Jesse J.
    Anvar, Seyed Yahya
    SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (603)
  • [40] Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-Based Outcomes
    Collett, Savannah
    Massmann, Amanda
    Petry, Natasha J. J.
    Van Heukelom, Joel
    Schultz, April
    Hellwig, Tadd
    Baye, Jordan F. F.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (03):
12345